BioXcel Therapeutics Inc BTAI:NASDAQ

Last Price$13.62Cboe Real-Time Last Sale as of 3:49PM ET 5/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.59(13.22%)
Bid (Size)$13.61 (10)
Ask (Size)$13.64 (38)
Day Low / High$12.30 - 13.92
Volume549.3 K
 

View Biotechnology IndustryPeer Comparison as of 05/17/2022

 

BioXcel Therapeutics Inc ( NASDAQ )

Price: $13.62
Change: +1.59 (13.22%)
Volume: 549.3 K
3:49PM ET 5/17/2022
 
 

Seres Therapeutics Inc ( NASDAQ )

Price: $3.58
Change: +0.01 (0.28%)
Volume: 665.6 K
3:48PM ET 5/17/2022
 
 

Rigel Pharmaceuticals Inc ( NASDAQ )

Price: $2.20
Change: +0.15 (7.32%)
Volume: 721.7 K
3:45PM ET 5/17/2022
 
 

Enochian Biosciences Inc ( NASDAQ )

Price: $6.27
Change: +0.26 (4.33%)
Volume: 90.3 K
3:48PM ET 5/17/2022
 
 

Outlook Therapeutics Inc ( NASDAQ )

Price: $1.61
Change: +0.01 (0.63%)
Volume: 361.3 K
3:48PM ET 5/17/2022
 

Read more news Recent News

--UBS Adjusts BioXcel Therapeutics Price Target to $18 From $27, Maintains Buy Rating
12:04PM ET 5/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Berenberg Bank Adjusts BioXcel Therapeutics Price Target to $69 From $73, Maintains Buy Rating
8:05AM ET 5/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (BTAI) BIOXCEL THERAPEUTICS Posts Q1 Loss $-1.12, vs. Street Est of $-1.09
7:03AM ET 5/09/2022 MT Newswires

...

BioXcel Therapeutics Launches Oncology Unit, Signs $260 Million in Financing Deals for Igalmi; Shares Rise Pre-Bell
7:40AM ET 4/19/2022 MT Newswires

BioXcel Therapeutics (BTAI) said Tuesday that it has created a wholly owned subsidiary called OnkosXcel Therapeutics, Inc. to develop transformative...

Company Profile

Business DescriptionBioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. View company web site for more details
Address555 Long Wharf Drive
New Haven, Connecticut 06511
Phone+1.475.238.6837
Number of Employees18
Recent SEC Filing05/09/20228-K
President, Chief Executive Officer & DirectorVimal D. Mehta
Chief Financial Officer & Vice PresidentRichard I. Steinhart
Chief Scientific Officer & Senior Vice PresidentFrank D. Yocca
Chief Medical Officer & Senior Vice PresidentVincent J. O'Neill

Company Highlights

Price Open$12.32
Previous Close$12.03
52 Week Range$9.08 - 39.00
Market Capitalization$381.2 M
Shares Outstanding28.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.10
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-48.25%

Analyst Ratings as of 03/11/2022

Buy
8
Overweight
0
Hold
0
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset